OCULAR THERAPEUTIX, INCOCUL
Market cap
$2.3B
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 2 | 2 | 3 | 4 |
| Stock-based compensation | 3 | 5 | 6 | 7 | 7 | 9 | 8 | 15 | 17 | 18 | 33 |
| Cash from operations | -20 | -34 | -34 | -50 | -49 | -78 | -54 | -66 | -60 | -70 | -135 |
| Capital expenditures | -1 | -2 | -2 | -8 | -2 | -2 | -1 | -1 | -4 | -6 | -1 |
| Cash from investing | -39 | -39 | 36 | 27 | -2 | -2 | -1 | -1 | -4 | -6 | -1 |
| Proceeds from issuance of term debt, net | - | - | - | - | - | - | - | - | - | 82 | - |
| Repayments of term debt | - | - | - | - | - | - | - | - | - | 26 | - |
| Cash from financing | 79 | 66 | 1 | 32 | 69 | 75 | 228 | 3 | 1 | 170 | 332 |
| Free cash flow | |||||||||||
| FCF margin (%) |